Developer docs
API playgroundTry for free, no card

Search company profiles

SBC Medical Group

Full company profile

uuid000ei7b

Namestring
SBC Medical Group
Legal namestring
SBC Medical Group Holdings Incorporated
Company typeenum
Public
Founded yearint
2000
Descriptiontext

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is a management services organization that provides operational, clinical, and branding support to a network of 283 franchise aesthetic healthcare clinics, anchored by the Shonan Beauty Clinic brand in Japan. Founded in 2000 and taken public via SPAC merger with Pono Capital 2 in September 2024, the company reports approximately $174 million in FY2025 revenue while the underlying franchise network generated $1.163 billion in total clinic revenue, with 6.63 million annual customer visits at a 72% repeat rate. The business model combines recurring franchise fees with equity-style returns from minority investments and consulting/managed services delivered to international partners.

The company's product surface spans a multi-brand portfolio: Shonan Beauty Clinic (mass-market Japanese aesthetic dermatology), NEO Skin Clinic (premium/VIP flagship targeting international patients, with Ginza location opened March 2026), The Chelsea Clinic (acquired via Singapore-based AHH in November 2024), and the SBC Wellness 2.0 longevity platform launched March 2026. Underlying technology includes a proprietary "Talk Bridge" multilingual interpretation app, AI-driven call center infrastructure credited with 31% labor reduction and 30% faster response times, and an AI-managed health platform leveraging data across the clinic network. New CTO Sheng-FU Hsiao, appointed March 1, 2026, leads the AI and digital transformation strategy.

Internationally, SBC has executed a coordinated expansion roadmap: AHH acquisition in Singapore (21 clinics, November 2024) as the regional hub, consulting agreement with BLEZ ASIA in Thailand (November 2025, with full dermatology launch June 2026), strategic minority equity investment in OrangeTwist covering 24 U.S. MedSpa locations across six states (January 2026), and a strategic alliance with Shanghai-based Daibi Medical Aesthetics (February 2026) to drive inbound medical tourism. The company holds approximately $164 million in cash against a market capitalization of $444–450 million, carries a $50 million shelf registration, a $20 million share repurchase authorization through December 2026, and has stated a public goal of reaching 1,000 clinics over a ten-year horizon.

Short descriptiontext

SBC Medical Group Holdings is a Nasdaq-listed management services organization that supports a network of 283 aesthetic healthcare franchise clinics, primarily under the Shonan Beauty Clinic brand in Japan, serving 6.6 million annual patient visits and expanding into Singapore, Thailand, the U.S., and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aesthetic healthcare services, medical clinic franchise, cosmetic surgery services, longevity wellness platform, dermatology clinic network
NAICS code1 code
  • Offices of Physicians6211
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Aesthetic Healthcare Clinics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Franchise Fee Revenue
TypeSubscription Recurring
Description

SBC Medical generates revenue primarily through franchise fees from its network of 283 affiliated clinic locations across Japan, providing management support, branding, protocols, and operational guidance.

morningstar.com
2Clinic Service Revenue
TypeTransaction Fee
Description

Revenue from total clinic operations including patient visits across the franchise network. Total clinic revenue reached $1,163 million in FY2025 with average revenue per customer of $316, up 11% year-over-year.

stocktitan.net
3Consulting and Management Services
TypeManaged Services
Description

Revenue from providing consulting services to international partners including BLEZ ASIA in Thailand and other ASEAN market entries, offering clinical protocol development and Japanese-quality aesthetic medicine expertise.

bitget.com
4Equity Investment Returns
TypeLicensing Royalties
Description

Returns from minority equity investments in partners like OrangeTwist in the U.S. market as part of Phase 1 global expansion strategy.

investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Franchise network with 283 clinic locations generating recurring franchise fees
ModelSubscriptionBilling cadenceAnnual
Notes

Franchise fee structure revised in 2024-2025, impacting reported revenue

morningstar.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 3 records shown
1NEO Skin Clinic
Description

Flagship aesthetic dermatology clinic brand with VIP accommodations targeting international patients

businesswire.com
+2 more records
Core offering1 text field

SBC Medical Group operates a franchise-based aesthetic healthcare and dermatology clinic network, with 283 affiliated clinic locations across Japan handling approximately 6.6 million annual patient visits under the flagship Shonan Beauty Clinic brand. The company provides end-to-end franchise management services including clinical protocols, branding, marketing, and operational infrastructure to affiliated clinics, while expanding internationally via equity investments, partnerships, and acquisitions in the U.S., Singapore, and Thailand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Revenue growth of 9.6% annually projected over next three years, reaching $222.7 million by 2029
+4 more records
Product overview1 text field

SBC Medical Group Holdings Incorporated is a Nasdaq-listed Medical Services Organization that operates a multi-brand portfolio of aesthetic healthcare clinics and wellness platforms. The core offering centers on the Shonan Beauty Clinic brand (283 franchise locations), supported by the newer NEO Skin Clinic sub-brand targeting premium international patients. The company provides end-to-end management support including clinical protocols, technology integration, and operational infrastructure. Growth strategy includes organic expansion (SBC Wellness 2.0 longevity platform), strategic M&A (AHH acquisition in Singapore, Waqoo), and international partnerships (OrangeTwist in the U.S., BLEZ ASIA in Thailand). AI-driven transformation is underway under new CTO leadership, leveraging 6.63 million annual patient visits to build an automated management infrastructure.

Product and service6 records
1Shonan Beauty Clinic
CategoryAesthetic Healthcare Clinics
2NEO Skin Clinic
CategoryAesthetic Healthcare Clinics
3SBC Wellness 2.0
CategoryWellness Platform
4OrangeTwist
CategoryAesthetic Healthcare Clinics
5The Chelsea Clinic
CategoryAesthetic Healthcare Clinics
6BLEZ CLINIC
CategoryAesthetic Healthcare Clinics
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Daibi Medical Aesthetics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Strategic alliance between Medical Corporation Nasukai (operator of Shonan Beauty Clinic) and Shanghai-based Daibi Medical Aesthetics. Collaboration aims to share clinical expertise and operational know-how, enhance Shonan Beauty Clinic brand recognition in China, and support inbound medical tourism to Japan. Inbound visits nearly tripled from ~600 in early 2024 to ~1,700 by end of 2025.

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-05
Description

Strategic minority equity investment and partnership with U.S.-based MedSpa chain operating 24 locations across 6 states (California, Texas, Washington, Nevada, Colorado, New Jersey). Collaboration on clinical protocols, technology integration, and operational scalability. Forms Phase 1 of SBC's multi-year global expansion roadmap. OrangeTwist also acquired 6 additional locations in Colorado and Nevada in conjunction with the partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Consulting agreement for management support of dermatological clinic in Bangkok's Asok district. SBC provides clinical protocol development, Japanese-quality standards, and assists in selecting medical devices. Operations expected to commence by year-end with full aesthetic dermatology launch in June 2026. Partnership represents next step in ASEAN expansion following Singapore launch, targeting Thai market projected to reach USD 1.118 billion by 2033.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Academic collaboration following November 2025 MoU signing. Thai specialists observed Shonan Beauty Clinic operations, participated in physician education sessions, and discussed treatment protocols for Asian skin types. First concrete step in promoting international academic exchange as part of global expansion strategy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-14
Description

Tender offer to acquire 575,000 shares at JPY 1,900 per share, aimed at accelerating Waqoo's research and development efforts. Tender offer process scheduled between November 14 and December 12, 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Definitive agreement to acquire Singapore-based AHH operating 21 aesthetic medical clinics across four brands. All-cash transaction marked SBC's first step in acquisition-driven growth strategy, positioning Singapore as regional hub to expand across Asian markets. The Chelsea Clinic flagship brand relocated to Ngee Ann City.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical company whose Allergan Aesthetics division supplies Botox, CoolSculpting and the Juvederm franchise — the supply-side backbone of many aesthetic clinics. Comparable to SBC as a critical player in the aesthetic medicine value chain, although positioned as a product supplier rather than a clinic operator.

TypeBroad incumbent
Description

Asia-listed (KLSE, SGX) hospital operator with presence in Malaysia, Singapore, Turkey, India and Greater China. Comparable to SBC as a multi-country Asian healthcare services provider with expansion ambitions, although focused on tertiary hospitals rather than aesthetic clinics.

TypeBroad incumbent
Description

Japan-listed consumer-products and beauty conglomerate with growing aesthetic and skincare operations. Comparable to SBC as a Japanese consumer-beauty platform, but at much larger scale with mostly non-medical product offerings.

TypeDirect peer
Description

One of the largest U.S. medspa chains offering laser hair removal, injectables and body-contouring across ~150 locations. Closest direct comp to SBC's Shonan Beauty Clinic franchise model in terms of service mix (laser hair removal, anti-aging) and consumer positioning, validating the franchise-clinic concept in a more developed market.

TypeDirect peer
Description

U.S. medspa franchise with ~180 locations concentrated in the Western U.S., offering laser hair removal, skin treatments and injectables. Comparable to SBC in franchise-style geographic expansion, aesthetic service mix and consumer target demographic.

TypeBroad incumbent
Description

Public dermatology-focused aesthetics company (SIX-listed spin-off from Nestlé) selling fillers, botulinum toxin and skincare. Comparable to SBC as a global aesthetics/dermatology incumbent that the SBC network partners with and competes against for patient share.

TypeOthers
Description

NASDAQ-listed developer of aesthetic medical devices (body contouring, skin treatment, hair removal lasers). Comparable to SBC as an enabling infrastructure provider whose devices are used inside Shonan Beauty Clinic and NEO Skin Clinic locations.

TypeBroad incumbent
Description

Japanese personal-care and prestige-beauty conglomerate with a large aesthetic dermatology and clinic footprint across Asia. Comparable to SBC as a Japan-anchored incumbent in aesthetic medicine and dermatology, although Shiseido's clinic operations are part of a much broader cosmetics portfolio.

TypeDirect peer
Description

Public company (SKIN) commercialising the Hydrafacial system and treatment network across providers and medspas globally. Comparable to SBC's aesthetic-treatment platform model with recurring service revenue and a focus on the high-end consumer aesthetic experience.

TypeEmerging player
Description

NYSE-listed direct-to-consumer wellness and aesthetics platform with a subscription/recurring-revenue model. Comparable to SBC in consumer-facing aesthetics and recurring revenue characteristics, although Hims & Hers is virtual-first rather than clinic-based.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SBC Medical Group

Aesthetic Healthcare Clinicssbc-holdings.com

SBC Medical Group Holdings is a Nasdaq-listed management services organization that supports a network of 283 aesthetic healthcare franchise clinics, primarily under the Shonan Beauty Clinic brand in Japan, serving 6.6 million annual patient visits and expanding into Singapore, Thailand, the U.S., and China.

What SBC Medical Group does

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is a management services organization that provides operational, clinical, and branding support to a network of 283 franchise aesthetic healthcare clinics, anchored by the Shonan Beauty Clinic brand in Japan. Founded in 2000 and taken public via SPAC merger with Pono Capital 2 in September 2024, the company reports approximately $174 million in FY2025 revenue while the underlying franchise network generated $1.163 billion in total clinic revenue, with 6.63 million annual customer visits at a 72% repeat rate. The business model combines recurring franchise fees with equity-style returns from minority investments and consulting/managed services delivered to international partners.

The company's product surface spans a multi-brand portfolio: Shonan Beauty Clinic (mass-market Japanese aesthetic dermatology), NEO Skin Clinic (premium/VIP flagship targeting international patients, with Ginza location opened March 2026), The Chelsea Clinic (acquired via Singapore-based AHH in November 2024), and the SBC Wellness 2.0 longevity platform launched March 2026. Underlying technology includes a proprietary "Talk Bridge" multilingual interpretation app, AI-driven call center infrastructure credited with 31% labor reduction and 30% faster response times, and an AI-managed health platform leveraging data across the clinic network. New CTO Sheng-FU Hsiao, appointed March 1, 2026, leads the AI and digital transformation strategy.

Internationally, SBC has executed a coordinated expansion roadmap: AHH acquisition in Singapore (21 clinics, November 2024) as the regional hub, consulting agreement with BLEZ ASIA in Thailand (November 2025, with full dermatology launch June 2026), strategic minority equity investment in OrangeTwist covering 24 U.S. MedSpa locations across six states (January 2026), and a strategic alliance with Shanghai-based Daibi Medical Aesthetics (February 2026) to drive inbound medical tourism. The company holds approximately $164 million in cash against a market capitalization of $444–450 million, carries a $50 million shelf registration, a $20 million share repurchase authorization through December 2026, and has stated a public goal of reaching 1,000 clinics over a ten-year horizon.

SBC Medical Group firmographics

Firmographics
Name
SBC Medical Group
Legal name
SBC Medical Group Holdings Incorporated
Website
https://sbc-holdings.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
SBC Medical Group Holdings is a Nasdaq-listed management services organization that supports a network of 283 aesthetic healthcare franchise clinics, primarily under the Shonan Beauty Clinic brand in Japan, serving 6.6 million annual patient visits and expanding into Singapore, Thailand, the U.S., and China.
Ownership category
akta.pro rank

Where SBC Medical Group is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices4 records

Markets served

SBC Medical Group business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Franchise Fee Revenue: SBC Medical generates revenue primarily through franchise fees from its network of 283 affiliated clinic locations across Japan, providing management support, branding, protocols, and operational guidance.
  2. Clinic Service Revenue: Revenue from total clinic operations including patient visits across the franchise network. Total clinic revenue reached $1,163 million in FY2025 with average revenue per customer of $316, up 11% year-over-year.
  3. Consulting and Management Services: Revenue from providing consulting services to international partners including BLEZ ASIA in Thailand and other ASEAN market entries, offering clinical protocol development and Japanese-quality aesthetic medicine expertise.
  4. Equity Investment Returns: Returns from minority equity investments in partners like OrangeTwist in the U.S. market as part of Phase 1 global expansion strategy.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualFranchise network with 283 clinic locations generating recurring franchise fees

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

SBC Medical Group product offering

Product offering

Core offering

SBC Medical Group operates a franchise-based aesthetic healthcare and dermatology clinic network, with 283 affiliated clinic locations across Japan handling approximately 6.6 million annual patient visits under the flagship Shonan Beauty Clinic brand. The company provides end-to-end franchise management services including clinical protocols, branding, marketing, and operational infrastructure to affiliated clinics, while expanding internationally via equity investments, partnerships, and acquisitions in the U.S., Singapore, and Thailand.

Product overview

SBC Medical Group Holdings Incorporated is a Nasdaq-listed Medical Services Organization that operates a multi-brand portfolio of aesthetic healthcare clinics and wellness platforms. The core offering centers on the Shonan Beauty Clinic brand (283 franchise locations), supported by the newer NEO Skin Clinic sub-brand targeting premium international patients. The company provides end-to-end management support including clinical protocols, technology integration, and operational infrastructure. Growth strategy includes organic expansion (SBC Wellness 2.0 longevity platform), strategic M&A (AHH acquisition in Singapore, Waqoo), and international partnerships (OrangeTwist in the U.S., BLEZ ASIA in Thailand). AI-driven transformation is underway under new CTO leadership, leveraging 6.63 million annual patient visits to build an automated management infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

  • NEO Skin Clinic: Flagship aesthetic dermatology clinic brand with VIP accommodations targeting international patients
  • The Chelsea Clinic
  • NEO Skin Clinic 銀座 (Ginza)

Products and services

  • Shonan Beauty Clinic
  • NEO Skin Clinic
  • SBC Wellness 2.0
  • OrangeTwist
  • The Chelsea Clinic
  • BLEZ CLINIC

Quantifiable outcome

  • Revenue growth of 9.6% annually projected over next three years, reaching $222.7 million by 2029
  • +4 more outcomes

Companies that use SBC Medical Group

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

SBC Medical Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

SBC Medical Group partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Daibi Medical AestheticscoreStrategic or Co-development Partner · 2 February 2026Strategic alliance between Medical Corporation Nasukai (operator of Shonan Beauty Clinic) and Shanghai-based Daibi Medical Aesthetics. Collaboration aims to share clinical expertise and operational know-how, enhance Shonan Beauty Clinic brand recognition in China, and support inbound medical tourism to Japan. Inbound visits nearly tripled from ~600 in early 2024 to ~1,700 by end of 2025.
  • OrangeTwistcoreStrategic or Co-development Partner · 5 January 2026Strategic minority equity investment and partnership with U.S.-based MedSpa chain operating 24 locations across 6 states (California, Texas, Washington, Nevada, Colorado, New Jersey). Collaboration on clinical protocols, technology integration, and operational scalability. Forms Phase 1 of SBC's multi-year global expansion roadmap. OrangeTwist also acquired 6 additional locations in Colorado and Nevada in conjunction with the partnership.
  • BLEZ ASIA Co., Ltd.coreStrategic or Co-development Partner · 14 November 2025Consulting agreement for management support of dermatological clinic in Bangkok's Asok district. SBC provides clinical protocol development, Japanese-quality standards, and assists in selecting medical devices. Operations expected to commence by year-end with full aesthetic dermatology launch in June 2026. Partnership represents next step in ASEAN expansion following Singapore launch, targeting Thai market projected to reach USD 1.118 billion by 2033.
  • Chulabhorn International College of Medicine (CICM) at Thammasat UniversityminorStrategic or Co-development Partner · 14 November 2025Academic collaboration following November 2025 MoU signing. Thai specialists observed Shonan Beauty Clinic operations, participated in physician education sessions, and discussed treatment protocols for Asian skin types. First concrete step in promoting international academic exchange as part of global expansion strategy.
  • Waqoo, Inc.coreStrategic or Co-development Partner · 14 November 2025Tender offer to acquire 575,000 shares at JPY 1,900 per share, aimed at accelerating Waqoo's research and development efforts. Tender offer process scheduled between November 14 and December 12, 2025.
  • Aesthetic Healthcare Holdings Pte. Ltd. (AHH)coreStrategic or Co-development Partner · 13 November 2024Definitive agreement to acquire Singapore-based AHH operating 21 aesthetic medical clinics across four brands. All-cash transaction marked SBC's first step in acquisition-driven growth strategy, positioning Singapore as regional hub to expand across Asian markets. The Chelsea Clinic flagship brand relocated to Ngee Ann City.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

SBC Medical Group competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan Aesthetics): Global pharmaceutical company whose Allergan Aesthetics division supplies Botox, CoolSculpting and the Juvederm franchise — the supply-side backbone of many aesthetic clinics. Comparable to SBC as a critical player in the aesthetic medicine value chain, although positioned as a product supplier rather than a clinic operator.
  • IHH Healthcare: Asia-listed (KLSE, SGX) hospital operator with presence in Malaysia, Singapore, Turkey, India and Greater China. Comparable to SBC as a multi-country Asian healthcare services provider with expansion ambitions, although focused on tertiary hospitals rather than aesthetic clinics.
  • Kao Corporation: Japan-listed consumer-products and beauty conglomerate with growing aesthetic and skincare operations. Comparable to SBC as a Japanese consumer-beauty platform, but at much larger scale with mostly non-medical product offerings.
  • Galderma: Public dermatology-focused aesthetics company (SIX-listed spin-off from Nestlé) selling fillers, botulinum toxin and skincare. Comparable to SBC as a global aesthetics/dermatology incumbent that the SBC network partners with and competes against for patient share.
  • Shiseido: Japanese personal-care and prestige-beauty conglomerate with a large aesthetic dermatology and clinic footprint across Asia. Comparable to SBC as a Japan-anchored incumbent in aesthetic medicine and dermatology, although Shiseido's clinic operations are part of a much broader cosmetics portfolio.

Direct peers

  • Ideal Image: One of the largest U.S. medspa chains offering laser hair removal, injectables and body-contouring across ~150 locations. Closest direct comp to SBC's Shonan Beauty Clinic franchise model in terms of service mix (laser hair removal, anti-aging) and consumer positioning, validating the franchise-clinic concept in a more developed market.
  • LaserAway: U.S. medspa franchise with ~180 locations concentrated in the Western U.S., offering laser hair removal, skin treatments and injectables. Comparable to SBC in franchise-style geographic expansion, aesthetic service mix and consumer target demographic.
  • Beauty Health Company (Hydrafacial): Public company (SKIN) commercialising the Hydrafacial system and treatment network across providers and medspas globally. Comparable to SBC's aesthetic-treatment platform model with recurring service revenue and a focus on the high-end consumer aesthetic experience.

Others

  • InMode: NASDAQ-listed developer of aesthetic medical devices (body contouring, skin treatment, hair removal lasers). Comparable to SBC as an enabling infrastructure provider whose devices are used inside Shonan Beauty Clinic and NEO Skin Clinic locations.

Emerging players

  • Hims & Hers Health: NYSE-listed direct-to-consumer wellness and aesthetics platform with a subscription/recurring-revenue model. Comparable to SBC in consumer-facing aesthetics and recurring revenue characteristics, although Hims & Hers is virtual-first rather than clinic-based.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

SBC Medical Group social profiles

Digital presence

SBC Medical Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SBC Medical Group leadership team

Management profile

Number of profiles

Profiles5 records

SBC Medical Group subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

SBC Medical Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SBC Medical Group M&A and investment

M&A and investment

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SBC Medical Group

What does SBC Medical Group do?

SBC Medical Group operates a franchise-based aesthetic healthcare and dermatology clinic network, with 283 affiliated clinic locations across Japan handling approximately 6.6 million annual patient visits under the flagship Shonan Beauty Clinic brand. The company provides end-to-end franchise management services including clinical protocols, branding, marketing, and operational infrastructure to affiliated clinics, while expanding internationally via equity investments, partnerships, and acquisitions in the U.S., Singapore, and Thailand.

Is SBC Medical Group a public or private company?

SBC Medical Group is a public company. It is classified as public and is currently operating.

When was SBC Medical Group founded?

SBC Medical Group was founded in 2000. It employs 5,001 to 10,000 people.

Where is SBC Medical Group based?

SBC Medical Group is headquartered in Tokyo, Japan, in the Asia region.

How does SBC Medical Group make money?

Four revenue lines are on record. Franchise Fee Revenue is the primary driver. The others are clinic Service Revenue, consulting and Management Services and equity Investment Returns.

Who are SBC Medical Group's main competitors?

Broad incumbents on record are AbbVie (Allergan Aesthetics), IHH Healthcare, Kao Corporation, Galderma and Shiseido. Direct peers are Ideal Image, LaserAway and Beauty Health Company (Hydrafacial). InMode is listed as an others. Hims & Hers Health is listed as an emerging player.

Does SBC Medical Group have an API?

No public API is recorded for SBC Medical Group.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Markets DailySBC Medical Group (NASDAQ:SBC) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded SBC Medical Group from buy to strong-buy, while Weiss Ratings downgraded it to hold. The stock has a consensus rating of Moderate Buy with a target price of $8.50, and the company reported Q2 EPS of $0.10, missing the $0.12 consensus.American Banking and Market NewsHead to Head Review: SBC Medical Group (NASDAQ:SBC) versus Centene (NYSE:CNC)SBC Medical Group and Centene are compared across risk, valuation, dividends, analyst ratings, profitability, institutional ownership, and earnings. SBC Medical Group beats Centene on 10 of 15 factors, with a consensus price target of $8.50 versus $70.05 for Centene.Defense WorldComparing SBC Medical Group (NASDAQ:SBC) and DaVita (NYSE:DVA)DaVita and SBC Medical Group are compared on profitability, earnings, valuation, and analyst ratings. DaVita has higher revenue and earnings, but SBC Medical Group trades at a lower P/E ratio and has a stronger consensus rating with higher upside. Analysts favor SBC Medical Group.Markets DailySBC Medical Group (NASDAQ:SBC) Stock Bumped Down to Buy by Wall Street ZenWall Street Zen downgraded SBC Medical Group from strong-buy to buy, while BTIG and Weiss also issued ratings. The company reported Q2 EPS of $0.10, missing the $0.12 consensus, but revenue of $49.19 million beat estimates. Institutional investors hold 60.82% of the stock.Defense WorldAnalyzing UnitedHealth Group (NYSE:UNH) and SBC Medical Group (NASDAQ:SBC)SBC Medical Group and UnitedHealth Group are compared on analyst ratings, risk, valuation, and profitability. SBC Medical Group has a lower price-to-earnings ratio and higher potential upside, while UnitedHealth Group beats on 8 of 15 factors. Analysts favor SBC Medical Group due to its higher upside.Markets DailySBC Medical Group (NASDAQ:SBC) Upgraded to “Strong-Buy” at Wall Street ZenWall Street Zen upgraded SBC Medical Group to a strong-buy rating, while BTIG and Weiss Ratings have buy and sell ratings respectively. The stock opened at $4.75, and the company reported Q2 EPS of $0.10, missing the $0.12 consensus. Analysts forecast fiscal-year EPS of $0.44.Ticker ReportSBC Medical Group (NASDAQ:SBC) & 111 (NASDAQ:YI) Financial SurveySBC Medical Group outperforms 111 on 12 of 14 financial factors, including higher earnings and institutional ownership. Analysts rate SBC Medical Group more favorably with a consensus price target of $8.50, implying 90.58% upside. The comparison highlights SBC's stronger profitability and institutional backing.Ticker ReportSBC Medical Group (NASDAQ:SBC) versus HealthEquity (NASDAQ:HQY) Head to Head AnalysisSBC Medical Group and HealthEquity are compared on dividends, earnings, valuation, and profitability. HealthEquity leads on revenue, earnings, and institutional ownership, but SBC Medical Group has a lower P/E ratio and higher analyst upside. Analysts rate SBC Medical Group more favorably, citing a 95.85% upside versus 20.73% for HealthEquity.Markets DailySBC Medical Group (NASDAQ:SBC) and HealthEquity (NASDAQ:HQY) Head to Head SurveyHealthEquity and SBC Medical Group are compared on profitability, valuation, and analyst ratings. HealthEquity has higher revenue and earnings but a lower price-to-earnings ratio, while SBC Medical Group shows higher upside potential. Analysts favor SBC Medical Group with a 106.31% upside versus HealthEquity's 16.44%.Markets DailyCritical Analysis: Community Health Systems (NYSE:CYH) & SBC Medical Group (NASDAQ:SBC)SBC Medical Group outperforms Community Health Systems on 9 of 14 factors, including profitability and analyst ratings. SBC's consensus target price of $8.50 implies a 106.31% upside, versus Community Health Systems' 2.43% upside. SBC also has lower volatility and higher insider ownership.